{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:57:51Z","timestamp":1781333871385,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejso.2026.111860","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:45:33Z","timestamp":1777995933000},"page":"111860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant docetaxel, cisplatin, and capecitabine in borderline-inoperable locally advanced oral cavity squamous cell carcinoma: A prospective observational study"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-1023","authenticated-orcid":false,"given":"Abhimanyu","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0913-6652","authenticated-orcid":false,"given":"Manu","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sehrawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Priya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Joyson Antony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Prasath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra Singh","family":"Chawra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3979-7742","authenticated-orcid":false,"given":"G.","family":"Vetrivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1249-3697","authenticated-orcid":false,"given":"Jyoti","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2026.111860_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejso.2026.111860_bib2","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejso.2026.111860_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104662","article-title":"Management of locally advanced oral cancers","volume":"105","author":"Dhar","year":"2020","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejso.2026.111860_bib4","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.oraloncology.2014.07.015","article-title":"Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers","volume":"50","author":"Patil","year":"2014","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejso.2026.111860_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.2003.06.146","article-title":"Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial","volume":"21","author":"Licitra","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111860_bib6","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Gorbounova V,et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.111860_bib7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/annonc\/mdt555","article-title":"Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial","volume":"25","author":"Bossi","year":"2014","journal-title":"Annals of oncology"},{"issue":"21","key":"10.1016\/j.ejso.2026.111860_bib8","doi-asserted-by":"crossref","first-page":"18707","DOI":"10.18632\/oncotarget.4531","article-title":"Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma","volume":"6","author":"Zhong","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejso.2026.111860_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0019-509X.112263","article-title":"Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: does it make a difference?","volume":"50","author":"Prabhash","year":"2013","journal-title":"Indian J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2026.111860_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/ijc.IJC_131_17","article-title":"Jacob L.A., et al. Induction chemotherapy in locally advanced T4b oral cavity squamous cell cancers: A regional cancer center experience","volume":"54","author":"Rudresha","year":"2017","journal-title":"Indian J Cancer"},{"issue":"17","key":"10.1016\/j.ejso.2026.111860_bib11","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejso.2026.111860_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial","volume":"14","author":"Haddad","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.111860_bib13","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","article-title":"Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer","volume":"32","author":"Cohen","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111860_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","article-title":"Capecitabine: a review","volume":"27","author":"Walko","year":"2005","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.ejso.2026.111860_bib15","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"Boyer M.,et al. First-line oral capecitabine therapy in metastatic colorectal cancer","volume":"13","author":"Cassidy","year":"2002","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2026.111860_bib16","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/hed.27119","article-title":"Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma","volume":"44","author":"Li","year":"2022","journal-title":"Head Neck"},{"issue":"7","key":"10.1016\/j.ejso.2026.111860_bib17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jamaoto.2015.0719","article-title":"Treatment factors associated with survival in early-stage oral cavity cancer: analysis of the national cancer data base","volume":"141","author":"Luryi","year":"2015","journal-title":"JAMA Otolaryngol Head Neck Surg"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326004798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326004798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:47:54Z","timestamp":1781333274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326004798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0748798326004798"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111860","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant docetaxel, cisplatin, and capecitabine in borderline-inoperable locally advanced oral cavity squamous cell carcinoma: A prospective observational study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111860","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111860"}}